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CASE REPORT
Complete remission after single agent 
blinatumomab in a patient with pre-B acute 
lymphoid leukemia relapsed and refractory 
to three prior regimens: hyperCVAD, high dose 
cytarabine mitoxantrone and CLAG
Katherine Linder, Deepthi Gandhiraj, Madhura Hanmantgad, Karen Seiter and Delong Liu*
Abstract 
Background: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combi-
nation chemotherapy.
Case presentation: We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this 
patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitox-
antrone/cytarabine and CLAG regimens.
Conclusion: This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single 
agent blinatumomab.
© 2016 Linder et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Adults with relapsed or refractory precursor B acute 
lymphoblastic leukemia have an unfavourable progno-
sis. The current standard of care for relapsed or refrac-
tory acute lymphoblastic leukemia (ALL) is combination 
chemotherapy which yields complete remission (CR) 
in 30–45 % of patients [1–5]. Cancer immunotherapy is 
being widely used nowadays for solid tumors as well as 
lymphomas. Chimeric antigen receptor-engineered T 
cells showed promise in the treatment of aggressive ALL 
and chronic lymphoid leukemia [6–9]. Blinatumomab 
is a bispecific T cell engager (BiTE) diabody construct 
with dual specificity for CD19 and CD3 [10–13]. Blina-
tumomab simultaneously binds CD3-positive cytotoxic 
T cells and CD19-positive B cells, resulting in T-cell-
mediated serial lysis of normal and malignant B cells 
[13]. Thus, blinatumomab represents an immunotherapy 
that engages patients’ endogenous T cells to attack and 
potentially eradicate B-precursor ALL blasts. Blinatu-
momab was first reported in a clinical phase I trial in 
38 patients with refractory non-Hodgkin lymphoma 
[11]. Blinatumomab has demonstrated promising activ-
ity and a favorable safety profile in relapsed/refractory 
(R/R) ALL and in ALL with minimal residual disease 
(MRD). A large, multicenter, phase II trial (MT103-211, 
NCT01466179) assessed blinatumomab in 189 adult 
patients with relapsed or refractory B cell ALL with 
Philadelphia chromosome (Ph) negativity [14]. 43  % of 
patients achieved CR or CRh within two cycles of treat-
ment with the single-agent blinatumomab. Median 
relapse-free survival was 5 to 9 months for those patients 
who achieved CR/CRh [14]. However, in this trial, only 
17 % of patients had more than two prior regimens.
We report here a highly refractory case of relapsed 
Ph− pre B ALL who achieved CR with a single cycle of 
blinatumomab.
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Case report
The patient is a 32 year old female at 24 weeks of gesta-
tion who presented in January 2014 with bilateral sub-
mandibular swelling and pain with radiation to head, 
neck, chest, and back for 2 weeks. On her initial presen-
tation she was found to have WBC 164 ×  109/L with a 
differential of 94.4 % lymphoblasts, platelets 27 × 109/L, 
and hemoglobin of 10.4 gm/dL. A peripheral blood flow 
cytometry revealed abnormal immature B cell population 
that comprised 90 % of the total cells and were positive 
for CD10, CD19, CD22, CD34, Tdt, but negative for CD 
20. These findings were characteristic for precursor B-cell 
ALL. Cytogenetics was negative for Philadelphia chro-
mosome. Karyotyping showed a normal 46XX chromo-
some display. FISH was negative for BCR/ABL and MLL 
gene rearrangement on chromosome 11q23.
Due to the pregnancy status, she underwent chemo-
therapy induction with the modified Linker regimen 
in 01/2014 [15–17]. This included cyclophosphamide 
(1 gm/m2) on day 1, vincristine 2 mg IV on days 1, 8, 15, 
22, 30, 37, and 44; daunorubicin 50 mg/m2 on days 1–3, 
30 and 31, and prednisone 100 mg po days 1–4, 80 mg on 
days 5–28, tapered slowly to off on day 62. Cerebral spi-
nal fluid was negative for malignant cells.
On day 38, she had a bone marrow biopsy revealing a 
hypocellular marrow, erythroid hyperplasia, dyseryth-
ropoiesis and atypical immature B-cells consistent with 
residual disease of precursor B-ALL. Concurrent flow 
cytometry of the aspirate showed an immature B-cell 
population (1.8 % of total B cells) expressing CD19, Tdt. 
Clinically she was in complete remission by standard 
definition with platelets 140 × 109/L absolute neutrophil 
count (ANC) 1.43 × 109/L.
She had C-section at gestation week 34 and delivered a 
healthy girl.
The second cycle of chemotherapy began 1  week post-
partum with standard hyperCVAD regimen B in 3/2014 
[18, 19]. She had Ommaya reservoir placed and received 
intrathecal methotrexate twice per cycle following the 
standard protocol defined in the hyperCVAD regimen. This 
was followed by six more cycles of hyperCVAD. Shortly 
after completion of last hyperCVAD, she started to have 
progressively worsening cytopenia. In November 2014, a 
bone marrow aspiration and biopsy were done to evaluate 
her disease status. The flow cytometry study of the aspi-
rate showed a 79 % lymphoblast population expressing the 
following markers: CD19, CD10, Tdt, and CD34. This was 
consistent with full relapse of her precursor B-cell ALL. 
Karyotyping was 46XX. The patient received re-induction 
chemotherapy with high dose cytarabine (3 gm/m2 daily IV 
over 3 h × 5), and mitoxantrone (60 mg/m2 once) [20].
A repeat bone marrow aspirate and biopsy was per-
formed in 1/2015 and revealed 43 % lymphoblasts. This 
confirmed persistent refractory precursor-B ALL. Sal-
vage chemotherapy with CLAG regimen (cladribine, 
cytarabine and G-CSF) was started immediately [21–23]. 
Four weeks later, a repeat bone marrow biopsy showed 
68 % lymphoblasts, consistent with refractory disease to 
the CLAG regimen.
In February 2015, she was treated with blinatumomab. 
She was started with 9  mcg/day. On day 3 of blinatu-
momab therapy, the patient started spiking fever to 
102.7  °F, with tachycardia and hypotension. The patient 
was transferred to the ICU for closer monitoring. Chem-
otherapy with blinatumomab was temporarily held for 
suspected cytokine release syndrome (CRS). The patient 
received one dose of tocilizumab 8  mg/kg IV once in 
addition to methylprednisolone. She required aggressive 
fluid resuscitation and was on vasopressors for 2  days. 
Blinatumomab was restarted 2 days later at 9 mcg/day. In 
total she received 9 days of blincyto at 9 mcg daily. The 
dose was increased to 28 mcg per day and continued to 
day 28. Her blood counts improved steadily. A bone mar-
row biopsy was performed. Flow cytometry of the aspi-
rate revealed no immature B-cell population. Pathology 
revealed trilineage hematopoiesis with no increase in 
blasts. A concurrent peripheral blood counts showed 
platelets of 247 ×  109/L and ANC  >  1 ×  109/L. At this 
point, the patient had a pathology documented com-
plete remission (CR) after one course of single agent 
blinatumomab.
Since she was not eligible for allogeneic hematopoietic 
stem cell transplantation (HSCT), maintenance chemo-
therapy with MTX, vincristine, pegylated asparaginase 
and dexamethasone was given. However, she developed 
acute pancreatitis after four cycles of the PEG-aspar-
aginase-containing regimen. Upon recovery from the 
pancreatitis, a bone marrow biopsy confirmed that the 
patient remained in CR in August 2015.
In September 2015, she was started on a 2-week cycle 
of blinatumomab as maintenance.  Due to lack of con-
vincing scientific data for using blinatumomab as main-
tenance treatment, further treatment with blinatumomab 
was stopped. She maintained normal blood counts and 
had normal activity. Unfortunately, in February 2016, 
her WBC increased to 16.4  ×  109/L, platelet counts 
decreased to 75  ×  109/L. Bone marrow biopsy at this 
point showed an abnormal immature B-cell population 
expressing CD19 (dim), CD22, CD10, CD34, TdT, HLA-
DR, CD9 and CD38 (heterogeneous). The findings were 
consistent with relapsed preB-ALL. Since CD19 was still 
positive, blinatumomab was started. Two weeks later, the 
WBC rose to 74.4 × 109/L, platelets down to 19 × 109/L. 
Peripheral blood had 71 % blasts. Therefore, her ALL was 
refractory to blinatumomab re-treatment. At the time of 
this report, she was receiving additional treatment.
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Discussion
The ALL in this patient relapsed quickly after completion 
of the hyperCVAD regimen and was refractory to high 
dose mitoxantrone/cytarabine and CLAG regimens. This 
highly refractory pre-B Ph− ALL was induced to com-
plete remission after one course of single agent blinatu-
momab. This is significant since there has been no case 
like this in our historical database that achieved CR. The 
median survival in this patient population is traditionally 
around 3 months.
Blinatumomab represents the first-in-class BiTE 
antibody approved by FDA for clinical use. This novel 
diabody opens a new channel of immunotherapy for 
patients with relapsed/refractory B cell ALL. However, 
the requirement for continuous IV infusion due to the 
small molecular weight and rapid clearance presents 
a challenge for clinical application. Newer tetravalent 
bispecific antibodies, AFM11 and AFM13, are being 
tested in clinical trials as weekly or twice weekly infusion 
[24, 25]. T cells with CD19/CD3 chimeric antigen recep-
tors (CAR-T19) have been shown to induce high remis-
sion rate (90 % CR in refractory ALL) [9, 26]. The rate of 
severe CRS associated with CAR-T therapy was reported 
to be 27  %. This rate was much higher than that of bli-
natumomab (2  %) [14]. CAR-T penetrates blood–brain 
barrier [9]. It remains unknown whether blinatumomab 
has similar property. The optimal treatment duration 
and schedule of blinatumomab for patients who can not 
receive allogeneic HSCT remain to be determined. The 
role of consolidation or maintenance therapy with blina-
tumomab also remains an area of investigation [13].
The patient had a prolonged remission after blina-
tumomab and PEG-asparaginase-containing regimen, 
but eventually relapsed and became refractory to blina-
tumomab re-treatment. One report found that PD-L1 
overexpression developed in the ALL cells refractory to bli-
natumomab [27]. Nivolumab was known to be highly active 
in refractory Hodgkin lymphoma [28]. It is unclear yet 
whether ALL relapsed after blinatumomab might respond 
to PD-1 antibodies. Novel agents with different mecha-
nisms of action, such as ABT-199 (venetoclax) and ACP-
196 (acalabrutinib) are being studied for highly refractory 
lymphoid malignancies [13, 29]. New therapeutic options 
are urgently needed for highly refractory ALL patients.
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